Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M279Revenue $M0.1Net Margin (%)-30,117.0Z-Score3.1
Enterprise Value $M191EPS $-0.6Operating Margin %-49,605.0F-Score3
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-30,116.0Higher ROA y-yY
Price/Book4.110-y EBITDA Growth Rate %-11.5Quick Ratio4.7Cash flow > EarningsN
Price/Sales2,7245-y EBITDA Growth Rate %5.9Current Ratio4.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-33.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-44.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M55.7ROI % (ttm)-43.5Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CYTRGeorge Soros 2014-06-30 Sold Out $2.92 - $5.31
($3.79)
$ 5.0124%Sold Out0
CYTRGeorge Soros 2014-03-31 Buy $3.18 - $8.08
($5.96)
$ 5.01-19%New holding81,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CYTR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.44105.33 view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.06143.2 view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.785.56 view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.6191.95 view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.5894.19 view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.6787.64 view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.5199.6 view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.5100.4 view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-2.53 view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$50.2 view

Press Releases about CYTR :

    Quarterly/Annual Reports about CYTR:

    News about CYTR:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
    Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
    Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
    CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
    CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
    CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
    CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
    CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
    CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
    CytRx Corp. Reports Operating Results (10-Q) Aug 08 2009 

    More From Other Websites
    8 Analyst Stocks Under $10 With Massive Upside Calls Apr 18 2015
    CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation Apr 17 2015
    Oppenheimer Jumps On CytRx Bandwagon Apr 17 2015
    Top Analyst Upgrades and Downgrades: Apple, CyberArk, EMC, Goldman Sachs, SanDisk, ULTA, Wayfair and... Apr 17 2015
    Coverage initiated on CytRx by Oppenheimer Apr 17 2015
    CYTRX CORP Financials Mar 14 2015
    Dr. Anita J. Chawla Joins CytRx Board of Directors to Add Additional Drug Commercialization... Mar 11 2015
    Dr. Anita J. Chawla Joins CytRx Board of Directors to Add Additional Drug Commercialization... Mar 11 2015
    CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Mar 11 2015
    CytRx reports 4Q loss Mar 10 2015
    CytRx reports 4Q loss Mar 10 2015
    CytRx Reports 2014 Financial Results Mar 10 2015
    CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 10 2015
    CytRx Reports 2014 Financial Results Mar 10 2015
    CytRx to Present at the Cowen & Company 35th Annual Health Care Conference Feb 25 2015
    CytRx to Present at the Cowen & Company 35th Annual Health Care Conference Feb 25 2015
    CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in... Feb 11 2015
    CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting... Feb 11 2015
    CytRx to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015 in New York... Feb 02 2015
    CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog Jan 26 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK